Research programme: arthritis therapy - IBEX
Latest Information Update: 18 Jan 2011
At a glance
- Originator IBEX Technologies
- Class Antibodies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Rheumatic disorders
Most Recent Events
- 01 Nov 2002 IBEX Technologies' arthritis therapy programme is available for licensing [http://www.ibex.ca]
- 01 Nov 2002 Preclinical trials in Rheumatic disorders in Canada (unspecified route)